{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:01:25Z","timestamp":1788177685784,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Anti-human epidermal growth factor receptor 2 (HER2) therapies are associated with interstitial lung disease (ILD), also referred to as pneumonitis. In this literature review, we describe the incidence of ILD among patients with HER2-positive metastatic breast cancer (MBC) receiving anti-HER2 therapies, and we describe existing recommendations for monitoring and managing drug-induced ILD among these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed and Embase to identify clinical trials and postmarket observational studies that investigated anti-HER2 therapies for HER2-positive MBC, reported on ILD, and were published during January 1, 2009 to July 15, 2019. Articles were screened by two researchers; data were extracted from the full-text articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 18 articles selected for this review assessed 9,886 patients who received trastuzumab (8 articles), lapatinib (4 articles), trastuzumab emtansine (3 articles), trastuzumab deruxtecan (2 articles), or trastuzumab duocarmazine (1 article). The overall incidence of all-grade ILD was 2.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009234), with 66.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009156) occurring as grade 1\u20132 events, 0.5% grade 3\u20134 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954; incidence), and 0.2% grade 5 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916; incidence). The highest ILD incidence (21.4%) was among patients receiving trastuzumab combined with everolimus and paclitaxel. Ten studies indicated that ILD events were managed via dose interruption, dose reduction, or treatment discontinuation; two studies included detailed guidelines on managing drug-induced ILD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ILD is a well-described adverse drug reaction associated with several anti-HER2 drugs. Published ILD management guidelines are available for few anti-HER2 treatment regimens; however, guidance for monitoring for anti-HER2 drug-induced ILD is lacking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-020-05754-8","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T11:36:08Z","timestamp":1593171368000},"page":"23-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer"],"prefix":"10.1007","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-895X","authenticated-orcid":false,"given":"Michelle D.","family":"Hackshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Taitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"5754_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5754_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000325746","volume":"15","author":"KA Goddard","year":"2012","unstructured":"Goddard KA, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C (2012) HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics 15(1):1\u201310. https:\/\/doi.org\/10.1159\/000325746","journal-title":"Public Health Genomics"},{"key":"5754_CR3","unstructured":"US Food and Drug Administration (2018) Herceptin prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103792s5345lbl.pdf"},{"key":"5754_CR4","unstructured":"US Food and Drug Administration (2019) Kadcyla prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125427s105lbl.pdf"},{"key":"5754_CR5","unstructured":"US Food and Drug Administration (2017) Nerlynx prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208051s000lbl.pdf"},{"key":"5754_CR6","unstructured":"US Food and Drug Administration (2018) Perjeta prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125409s123lbl.pdf"},{"key":"5754_CR7","unstructured":"US Food and Drug Administration (2018) Tykerb prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022059s024lbl.pdf"},{"issue":"6","key":"5754_CR8","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST4","volume":"200","author":"CR Sears","year":"2019","unstructured":"Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP (2019) Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis: an official American Thoracic Society research statement. Am J Respir Crit Care Med 200(6):e31\u2013e43. https:\/\/doi.org\/10.1164\/rccm.201906-1202ST4","journal-title":"Am J Respir Crit Care Med"},{"key":"5754_CR9","unstructured":"US Food and Drug Administration (2019) FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed October 15, 2019"},{"issue":"10","key":"5754_CR10","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/ijc.29887","volume":"138","author":"AE Willemsen","year":"2016","unstructured":"Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J (2016) mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int J Cancer 138(10):2312\u20132321. https:\/\/doi.org\/10.1002\/ijc.29887","journal-title":"Int J Cancer"},{"key":"5754_CR11","unstructured":"American Thoracic Society (2010) Interstitial lung disease. In: Schraufnagel DE (ed) Breathing in America: disease, progress, and hope"},{"key":"5754_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2213-0802-2-4","volume":"2","author":"KC Meyer","year":"2014","unstructured":"Meyer KC (2014) Diagnosis and management of interstitial lung disease. Transl Respir Med 2:4. https:\/\/doi.org\/10.1186\/2213-0802-2-4","journal-title":"Transl Respir Med"},{"issue":"4","key":"5754_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y, Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis, treatment of drug-induced lung injuries (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51(4):260\u2013277. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"issue":"Suppl 5","key":"5754_CR14","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1136\/thx.2008.101691","volume":"63","author":"AU Wells","year":"2008","unstructured":"Wells AU, Hirani N (2008) Interstitial lung disease guideline. Thorax 63(Suppl 5):v1\u2013v58. https:\/\/doi.org\/10.1136\/thx.2008.101691","journal-title":"Thorax"},{"key":"5754_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, Investigators DE-B (2019) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"New Engl J Med"},{"issue":"8","key":"5754_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124\u20131135. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"5754_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10549-015-3292-8","volume":"150","author":"C Acevedo-Gadea","year":"2015","unstructured":"Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM (2015) Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Res Treat 150(1):157\u2013167. https:\/\/doi.org\/10.1007\/s10549-015-3292-8","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5754_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canrad.2016.10.002","volume":"21","author":"Z Ajgal","year":"2017","unstructured":"Ajgal Z, de Percin S, Dieras V, Pierga JY, Campana F, Fourquet A, Kirova YM (2017) Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and\/or metastatic breast cancer: assessment of early toxicity. Cancer Radiother 21(2):114\u2013118. https:\/\/doi.org\/10.1016\/j.canrad.2016.10.002","journal-title":"Cancer Radiother"},{"issue":"6","key":"5754_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580\u2013591. https:\/\/doi.org\/10.1016\/S1470-2045(14)70138-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"5754_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/annonc\/mdp373","volume":"21","author":"G Capri","year":"2010","unstructured":"Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schutte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S (2010) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21(3):474\u2013480. https:\/\/doi.org\/10.1093\/annonc\/mdp373","journal-title":"Ann Oncol"},{"issue":"25","key":"5754_CR21","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","volume":"32","author":"V Dieras","year":"2014","unstructured":"Dieras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, Smitt MC, Krop IE (2014) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 32(25):2750\u20132757. https:\/\/doi.org\/10.1200\/JCO.2013.54.4999","journal-title":"J Clin Oncol"},{"issue":"7","key":"5754_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","volume":"16","author":"SA Hurvitz","year":"2015","unstructured":"Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D (2015) Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16(7):816\u2013829. https:\/\/doi.org\/10.1016\/S1470-2045(15)00051-0","journal-title":"Lancet Oncol"},{"issue":"3","key":"5754_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-013-2689-5","volume":"141","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, Andre F (2013) A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat 141(3):437\u2013446. https:\/\/doi.org\/10.1007\/s10549-013-2689-5","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5754_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/CBC.2009.n.004","volume":"9","author":"JR Infante","year":"2009","unstructured":"Infante JR, Yardley DA, Burris HA 3rd, Greco FA, Farley CP, Webb C, Spigel DR, Hainsworth JD (2009) Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 9(1):23\u201328. https:\/\/doi.org\/10.3816\/CBC.2009.n.004","journal-title":"Clin Breast Cancer"},{"issue":"1\u20132","key":"5754_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000318043","volume":"79","author":"A Jagiello-Gruszfeld","year":"2010","unstructured":"Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, DeSilvio M, Ridderheim M, Abbey R (2010) A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 79(1\u20132):129\u2013135. https:\/\/doi.org\/10.1159\/000318043","journal-title":"Oncology"},{"issue":"7","key":"5754_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H, TRs Collaborators (2014) Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689\u2013699. https:\/\/doi.org\/10.1016\/S1470-2045(14)70178-0","journal-title":"Lancet Oncol"},{"issue":"6","key":"5754_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","volume":"20","author":"K Tamura","year":"2019","unstructured":"Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 20(6):816\u2013826. https:\/\/doi.org\/10.1016\/S1470-2045(19)30097-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"5754_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","volume":"20","author":"Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F, International Breast Cancer Study G, the Breast International G","year":"2019","unstructured":"Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F, International Breast Cancer Study G, the Breast International G (2019) Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial. Lancet Oncol 20(3):371\u2013382. https:\/\/doi.org\/10.1016\/S1470-2045(18)30812-X","journal-title":"Lancet Oncol"},{"key":"5754_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","volume":"109","author":"F Montemurro","year":"2019","unstructured":"Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH (2019) Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer 109:92\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.022","journal-title":"Eur J Cancer"},{"issue":"5","key":"5754_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5732\/cjc.010.10507","volume":"30","author":"BH Xu","year":"2011","unstructured":"Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, Preston A, Martin AM, Chi HD, Wang L (2011) Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30(5):327\u2013335","journal-title":"Chin J Cancer"},{"issue":"6","key":"5754_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","volume":"20","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20(6):1026\u20131031. https:\/\/doi.org\/10.1093\/annonc\/mdn759","journal-title":"Ann Oncol"},{"issue":"3","key":"5754_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(15)00540-9","volume":"17","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M, LU-Bs Group (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17(3):357\u2013366. https:\/\/doi.org\/10.1016\/S1470-2045(15)00540-9","journal-title":"Lancet Oncol"},{"issue":"7","key":"5754_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107(7):1039\u20131046. https:\/\/doi.org\/10.1111\/cas.12966","journal-title":"Cancer Sci"},{"issue":"3","key":"5754_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T (2019) The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull 67(3):173\u2013185. https:\/\/doi.org\/10.1248\/cpb.c18-00744","journal-title":"Chem Pharm Bull"},{"issue":"20","key":"5754_CR35","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.ccr-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T (2016) DS-8201a, a novel HER2-Targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22(20):5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2822","journal-title":"Clin Cancer Res"},{"key":"5754_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N (2018) Drug-induced interstitial lung disease: a systematic review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm7100356","journal-title":"J Clin Med"},{"key":"5754_CR37","unstructured":"Afinitor prescribing information (2018) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022334s040,203985s013lbl.pdf"},{"issue":"17","key":"5754_CR38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer N (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"5754_CR39","unstructured":"ICH (1994) Clinical safety data management: definitions and standards for expedited reporting E2A. https:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/clinical-safety-data-management-definitions-and-standards-for-expedited-reporting.html"},{"key":"5754_CR40","unstructured":"NCI (2017) Common terminology criteria for adverse events (CTCAE), version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05754-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T19:38:26Z","timestamp":1624649906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5754"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05754-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MDH, JS, and CT are Daiichi Sankyo, Inc. employees. HED, AL, and MER are employees of RTI Health Solutions, an independent nonprofit research organization that performs contracted project work for medical device and pharmaceutical companies. DRC, HI, and CAP are consultants for Daiichi Sankyo, Inc. but have received no compensation for their contributions to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable for a literature review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable for a literature review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}